Evaluation of the effectiveness of modified CRD tests in the diagnosis of preeclampsia

Abstract

BACKGROUND: Preeclampsia is a multisystem complication of pregnancy associated with an increased risk of maternal / perinatal morbidity and mortality. In this regard, the development and following improvement of low-cost and convenient methods for diagnosis of preeclampsia is essential for accurate prediction, quick confirmation of the diagnosis and convenient monitoring of the pathology.

AIM: The aim of this study was to optimize a preeclampsia diagnosis test system based on the binding of proteins to the Congo red dye (CRD test).

MATERIALS AND METHODS: The study used 70 urine samples obtained from patients diagnosed with preeclampsia (n = 25) and from non-preeclampsia pregnant women (n = 45). The samples were stained with Congo red and the dye retention in the sample on the membrane after washing was calculated. Before staining, protein concentrations in the urine samples were equalized using centrifugal concentrators or the samples were used with the original protein concentrations. To wash the samples from the unbound dye, either methanol or ethanol was used. To compare the effectiveness of four CRD test variants differing in sample preparation, staining, and washing, ROC analysis was performed (IBM SPSS Statistics 20 software).

RESULTS: The express CRD test was designed as an optimization of the conventional CRD test. The effectiveness of the express test (the area under the ROC curve being 0.9) was higher than that of the other three test options (the area under the ROC curve ranges from 0.67 to 0.82). The developed express CRD test can provide 95% specificity and 73% sensitivity, which indicates the promise of using this method in clinical diagnostics for the specific detection of preeclampsia patients.

CONCLUSIONS: Optimization of the CRD test has provided more effective protocols for diagnosis of preeclampsia from urine samples using Congo red (express CRD test) and has simplified the routine application of this test in clinical practice.

Keywords

preeclampsia / Congo red / CRD test / diagnosis / pregnancy

References

[1] Say L, Chou D, Gemmill A, et al. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014;2(6):e323−333. DOI: 10.1016/S2214-109X(14)70227-X

[2] Say L., Chou D., Gemmill A., et al. Global causes of maternal death: a WHO systematic analysis // Lancet Glob. Health. 2014. Vol. 2. No. 6. P. e323−e33. DOI: 10.1016/S2214-109X(14)70227-X

[3] Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science. 2005;308(5728):1592−1594. DOI: 10.1126/science.1111726

[4] Redman C.W., Sargent I.L. Latest advances in understanding preeclampsia // Science. 2005. Vol. 308. N. 5728. P. 1592−1594. DOI: 10.1126/science.1111726

[5] Backes CH, Markham K, Moorehead P, et al. Maternal preeclampsia and neonatal outcomes. J Pregnancy. 2011;2011:214365. DOI: 10.1155/2011/214365

[6] Backes C.H., Markham K., Moorehead P., et al. Maternal preeclampsia and neonatal outcomes // J. Pregnancy. 2011. Vol. 2011. P. 214365. DOI: 10.1155/2011/214365

[7] El-Sayed AAF. Preeclampsia: A review of the pathogenesis and possible management strategies based on its pathophysiological derangements. Taiwan J Obstet Gynecol. 2017;56(5):593−598. DOI: 10.1016/j.tjog.2017.08.004

[8] El-Sayed A.A.F. Preeclampsia: A review of the pathogenesis and possible management strategies based on its pathophysiological derangements // Taiwan J. Obstet. Gynecol. 2017. Vol. 56. No. 5. P. 593−598. DOI: 10.1016/j.tjog.2017.08.004

[9] Malik A, Jee B, Gupta SK. Preeclampsia: Disease biology and burden, its management strategies with reference to India. Pregnancy Hypertens. 2019;15:23−31. DOI: 10.1016/j.preghy.2018.10.011

[10] Malik A., Jee B., Gupta S.K. Preeclampsia: Disease biology and burden, its management strategies with reference to India // Pregnancy Hypertens. 2015. Vol. 15. P. 23−31. DOI: 10.1016/j.preghy.2018.10.011

[11] Lowe SA, Brown MA, Dekker GA, et al. Guidelines for the management of hypertensive disorders of pregnancy 2008. Aust N Z J Obstet Gynaecol. 2009;49(3):242−246. DOI: 10.1111/j.1479-828X.2009.01003.x

[12] Lowe S.A., Brown M.A., Dekker G.A., et al. Guidelines for the management of hypertensive disorders of pregnancy 2008 // Aust. N. Z. J. Obstet. Gynaecol. 2009. Vol. 49. No. 3. P. 242−246. DOI: 10.1111/j.1479-828X.2009.01003.x

[13] Hypertension in pregnancy. Report of the american college of obstetricians and gynecologists’ task force on hypertension in pregnancy. Obstet Gynecol. 2013;122(5):1122−1131. DOI: 10.1097/01.AOG.0000437382.03963.88

[14] Hypertension in pregnancy. Report of the american college of obstetricians and gynecologists’ task force on hypertension in pregnancy // Obstet. Gynecol. 2013. Vol. 122. No. 5. P. 1122−1131. DOI: 10.1097/01.AOG.0000437382.03963.88

[15] Wu P, van den Berg C, Alfirevic Z, et al. Early pregnancy biomarkers in pre-eclampsia: a systematic review and meta-analysis. Int J Mol Sci. 2015;16(9):23035−23056. DOI: 10.3390/ijms160923035

[16] Wu P., van den Berg C., Alfirevic Z., et al. Early pregnancy biomarkers in pre-eclampsia: a systematic review and meta-analysis // Int. J. Mol. Sci. 2015. Vol. 16. No. 9. P. 23035−23056. DOI: 10.3390/ijms160923035

[17] Kosińska-Kaczyńska K, Wielgoś M. How to identify pregnant women at risk of pre-eclampsia? – a review of the current literature. Ginekol Pol. 2018;89(6):335−338. DOI: 10.5603/GP.a2018.0057

[18] Kosińska-Kaczyńska K., Wielgoś M. How to identify pregnant women at risk of pre-eclampsia? – a review of the current literature // Ginekol. Pol. 2018. R. 89. No. 6. S. 335−338. DOI: 10.5603/GP.a2018.0057

[19] Buhimschi IA, Nayeri UA, Zhao G, et al. Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia. Sci Transl Med. 2014;6(245):245ra92. DOI: 10.1126/scitranslmed.3008808

[20] Buhimschi I.A., Nayeri U.A., Zhao G., et al. Protein misfolding, congophilia, oligomerization, and defective amyloid processing in preeclampsia // Sci. Transl. Med. 2014. Vol. 6. No. 245. P. 245ra92. DOI: 10.1126/scitranslmed.3008808

[21] Gerasimova EM, Fedotov SA, Kachkin DV, et al. Protein misfolding during pregnancy: new approaches to preeclampsia diagnostics. Int J Mol Sci. 2019;20(24):6183. DOI: 10.3390/ijms20246183

[22] Gerasimova E.M., Fedotov S.A., Kachkin D.V., et al. Protein misfolding during pregnancy: new approaches to preeclampsia diagnostics // Int. J. Mol. Sci. 2019. Vol. 20. No. 24. P. 6183. DOI: 10.3390/ijms20246183

[23] Klinicheskie rekomendatsii. Preeklampsiya. Eklampsiya. Oteki, proteinuriya i gipertenzivnye rasstroistva vo vremya beremennosti, v rodakh i poslerodovom periode. 2021. [cited 2021 Dec 7]. Available from: https://mz.mosreg.ru/dokumenty/informaciya/klinicheskie-rekomendacii/06-07-2021-10-31-15-preeklampsiya-eklampsiya-oteki-proteinuriya-i-gipe

[24] Клинические рекомендации. Преэклампсия. Эклампсия. Отеки, протеинурия и гипертензивные расстройства во время беременности, в родах и послеродовом периоде. 2021. [дата обращения: 07.12.2021]. Доступно по ссылке: https://mz.mosreg.ru/dokumenty/informaciya/klinicheskie-rekomendacii/06-07-2021-10-31-15-preeklampsiya-eklampsiya-oteki-proteinuriya-i-gipe

[25] Edgington ES. Randomization tests. N.Y.: Marcel Dekker; 1995.

[26] Edgington E.S. Randomization tests. N.Y.: Marcel Dekker, 1995.

[27] Kamyshev NG, Iliadi KG, Bragina JV. Drosophila conditioned courtship: two ways of testing memory. Learn Mem. 1999;6(1):1−20.

[28] Kamyshev N.G., Iliadi K.G., Bragina J.V. Drosophila conditioned courtship: two ways of testing memory // Learn Mem. 1999. Vol. 6. No. 1. P. 1−20.

[29] Henderson AR. Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis. Ann Clin Biochem. 1993;30(Pt6):521−539. DOI: 10.1177/000456329303000601

[30] Henderson A.R. Assessing test accuracy and its clinical consequences: a primer for receiver operating characteristic curve analysis // Ann. Clin. Biochem. 1993. Vol. 30. Pt. 6. P. 521−539. DOI: 10.1177/000456329303000601

[31] Brown MA, Buddle ML. Inadequacy of dipstick proteinuria in hypertensive pregnancy. Aust N Z J Obstet Gynaecol. 1995;35(4):366−369. DOI: 10.1111/j.1479-828x.1995.tb02143.x

[32] Brown M.A., Buddle M.L. Inadequacy of dipstick proteinuria in hypertensive pregnancy // Aust. N. Z. J. Obstet. Gynaecol. 1995. Vol. 35. No. 4. P. 366−369. DOI: 10.1111/j.1479-828x.1995.tb02143.x

[33] Monte S. Biochemical markers for prediction of preclampsia: review of the literature. J Prenat Med. 2011;5(3):69−77.

[34] Monte S. Biochemical markers for prediction of preclampsia: review of the literature // J Prenat Med. 2011. Vol. 5. No. 3. P. 69−77.

[35] Sibai BM. Imitators of severe pre-eclampsia. Semin Perinatol. 2009;33(3):196−205. DOI: 10.1053/j.semperi.2009.02.004

[36] Sibai B.M. Imitators of severe pre-eclampsia // Semin. Perinatol. 2009. Vol. 33. No. 3. P. 196−205. DOI: 10.1053/j.semperi.2009.02.004

[37] Pourrat O, Coudroy R, Pierre F. Differentiation between severe HELLP syndrome and thrombotic microangiopathy, thrombotic thrombocytopenic purpura and other imitators. Eur J Obstet Gynecol Reprod Biol. 2015;189:68−72. DOI: 10.1016/j.ejogrb.2015.03.017

[38] Pourrat O., Coudroy R., Pierre F. Differentiation between severe HELLP syndrome and thrombotic microangiopathy, thrombotic thrombocytopenic purpura and other imitators // Eur. J. Obstet. Gynecol. Reprod. Biol. 2015. Vol. 189. P. 68−72. DOI: 10.1016/j.ejogrb.2015.03.017

[39] Buhimschi IA, Zhao G, Funai EF, et al. Proteomic profiling of urine identifies specific fragments of SERPINA1 and albumin as biomarkers of preeclampsia. Am J Obstet Gynecol. 2008;199(5):551.e1−551.e5516. DOI: 10.1016/j.ajog.2008.07.006

[40] Buhimschi I.A., Zhao G., Funai E.F., et al. Proteomic profiling of urine identifies specific fragments of SERPINA1 and albumin as biomarkers of preeclampsia // Am. J. Obstet. Gynecol. 2008. Vol. 199. No. 5. P. 551.e1−551.e5516. DOI: 10.1016/j.ajog.2008.07.006

[41] Kurtoglu E, Avci B, Kokcu A, et al. Serum VEGF and PGF may be significant markers in prediction of severity of preeclampsia. J Matern Fetal Neonatal Med. 2016;29(12):1987−1992. DOI: 10.3109/14767058.2015.1072157

[42] Kurtoglu E., Avci B., Kokcu A., et al. Serum VEGF and PGF may be significant markers in prediction of severity of preeclampsia // J. Matern. Fetal. Neonatal. Med. 2016. Vol. 29. No. 12. P. 1987−1992. DOI: 10.3109/14767058.2015.1072157

[43] Sovio U, Gaccioli F, Cook E. Prediction of preeclampsia using the soluble fms-like tyrosine kinase 1 to placental growth factor ratio: a prospective cohort study of unselected nulliparous women. Hypertension. 2017;69(4):731−738. DOI: 10.1161/HYPERTENSIONAHA.116.08620

[44] Sovio U., Gaccioli F., Cook E. Prediction of preeclampsia using the soluble fms-like tyrosine kinase 1 to placental growth factor ratio: a prospective cohort study of unselected nulliparous women // Hypertension. 2017. Vol. 69. No. 4. P. 731−738. DOI: 10.1161/HYPERTENSIONAHA.116.08620

[45] Millen KR, Buhimschi CS, Zhao G. Serum and urine thioflavin-t-enhanced fluorescence in severe preeclampsia. Hypertension. 2018;71(6):1185−1192. DOI: 10.1161/HYPERTENSIONAHA.118.11034

[46] Millen K.R., Buhimschi C.S., Zhao G. Serum and urine thioflavin-t-enhanced fluorescence in severe preeclampsia // Hypertension. 2018. Vol. 71. No. 6. P. 1185−1192. DOI: 10.1161/HYPERTENSIONAHA.118.11034

RIGHTS & PERMISSIONS

Fedotov S.A., Gerasimova E.M., Vashukova E.S., Pakin V.S., Kapustin R.V., Pachuliya O.V., Glotov A.S., Kulichikhin K.Y., Chernoff Y.O., Rubel A.A.